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Abstract : Alzheimer’s disease （AD） manifests early with prominent olfactory 
dysfunction.  The olfactory symptoms appear long before cognitive impairment 
and other typical AD symptoms.  Here, we tested odor detection and recogni-
tion acuity in AD patients and in age-matched controls to determine the 
relationships between olfactory test scores and anxiety level, cognitive function, 
and disease and therapy duration.
　We found that while AD patients had the same odor detection sensitivity 
as healthy subjects, most patients exhibited impaired odor recognition.  AD 
patients had signicantly lower cognitive function and trait anxiety scores than 
healthy subjects according to our assessments using the Mini-Mental State 
Examination （MMSE）.  Trait anxiety scores are thought to be lower in AD 
patients because of atrophy of the limbic system, particularly the amygdala 
（AMG）.  It has been reported that trait anxiety level is dependent on amyg-
dala activity, therefore, the low activation of the AMG is linked to reduced 
trait anxiety in AD.
　However, we found that trait anxiety correlated positively with odor detec-
tion ability in AD patients.  Although the function of the AMG is reduced 
in AD patients, it still contributes to odor detection in AD patients with high 
trait anxiety.
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Introduction
　Neurodegenerative disorders such as Parkinson’s disease （PD）1, 2） and Alzheimer’s disease 
（AD）3, 4） manifest early with prominent olfactory dysfunction.  In AD patients, the olfactory 
symptoms appear long before cognitive impairment and other typical AD symptoms 3）.
　Olfactory information is projected directly to the limbic system, bypassing the thalamus. 
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Human neuroimaging studies have shown that odor presentation activates the piriform （Pir） 
cortex, amygdala （AMG）, hippocampus （HI）, and orbitofrontal cortex （OFC） during 5, 6）. 
The Pir cortex, AMG, entorhinal cortex （ENT）, and HI are involved in odor detection, 
memory retrieval, and emotional evaluation （pleasant or unpleasant）, whereas the OFC 
plays a role in odor recognition ltered through emotion and memory via activation of the 
AMG and HI 7）, which are brain regions involved in emotion and memory recognition.
　We have examined odor detection and recognition acuity in PD patients and age-matched 
controls to determine the relationship between olfactory test scores and the function of 
brain regions involved in olfactory processing8）.  All PD patients were able to detect odors 
to the same sensitivity as normal healthy subjects but had difculty in recognizing odors8）. 
ENT is thought to play a role in odor detection and might also be involved in odor recog-
nition.  PD patients, who have impaired odor recognition but normal odor detection sensitiv-
ity, have decreased activation of ENT and limbic areas.  It is also possible that the lower 
activity of these areas in PD patients might be below the threshold required to activate the 
OFC.
　In AD, olfactory impairment is observed before the appearance of typical AD symptoms 3）. 
To assist in predicting AD onset and in managing early treatment before the classic signs 
of the disease appear, it is important to understand the relationship between olfactory 
impairment and disease and therapy durations, and between olfactory decit and cognitive 
function.  To gain an understanding of these relationships, we tested odor detection and rec-
ognition acuity in AD patients and in age-matched controls and analyzed the relationships 
between olfactory test scores and anxiety level, cognitive function, and disease and therapy 
duration.
Method
　Sixteen healthy normal subjects （mean 77.2±5.1 years of age ; all men） and 16 age-
matched patients with AD （mean 79.6±5.8 years of age ; nine men and seven women） 
participated in this study.  Diagnosis was based on clinical history as well as neurological 
and neuropsychological examinations, and was supported by structural and functional imag-
ing.  The AD patients were taking donepezil.  All participants undertook the Mini-Mental 
State Examination （MMSE）9）, for assessment of their cognitive function, and the Spielberger 
State-Trait Anxiety Inventory （STAI）10）, to measure their anxiety levels.
　All subjects gave informed consent, and the study was approved by the ethics committee 
of the Showa University School of Medicine.
Olfactory test
　The olfactory test has been explained in detail elsewhere 7, 8）.  Odor detection and recogni-
tion acuity were tested with a T&T olfactometer （Takasuna Co., Ltd., Tokyo, Japan） prior 
to commencement of the experiments.  The results of these tests correlated positively with 
53Olfaction in Alzheimer’s Disease
those obtained by using the University of Pennsylvania Smell Identification Test11）.  We 
tested ve odors using the olfactometer including β-phenyl ethyl alcohol （odor A）, methyl 
cyclopentenolone （odor B）, isovaleric acid （odor C）, γ-undecalactone （odor D）, and skatole 
（odor E）.  Each odorant was dissolved in propylene glycol and presented to the subjects in 
eight different concentrations and each consecutive concentration was 10 times stronger than 
the last.  Concentrations were labeled from -2 to ＋5, being equal to a normal subject’s 
detection （odor A, 10-5.2 ppb ; odor B, 10-5.6 ppb ; odor C, 10-6.0 ppb ; odor C ; 10-6.0 ppb ; 
odor D, 10-5.1 ppb ; odor E, 10-6.1 ppb）.  The above odorants corresponded to the aroma 
of a rose or sweet odor （odor A）, caramel or burnt sugar （odor B）, rotten food or sweaty 
clothes （odor C）, peach or sweet fruit （odor D）, and fecal material or kitchen refuse （odor 
E）.  Subjects were presented with the end （＞1 cm） of a strip of litmus paper （14 cm×
7 mm wide） that had been dipped into a bottle containing the odorant.  The ve odorants 
were presented randomly but at the same concentration for each trial.  The trials began 
with the lowest concentration of the odorants and were then repeated with progressively 
higher concentrations.  The odorants were presented for 30 s each with an interval of 45 s 
between each presentation to minimize adaptation 12）.  At the end of each trial, the subjects 
were asked if they had perceived an odor.  The concentration at which the odor was per-
ceived but not identied was considered to be the detection level.  The subjects were also 
asked if they could identify and describe the odors.  As the concentration of the odorant 
increased, the subjects were able to identify the odors.  The concentration at which an odor 
was rst identied was considered to be the recognition level.  The odor detection threshold 
for each subject was expressed as the average of threshold scores for each odor.  The rec-
ognition threshold was expressed in the same manner.
Data analysis
　All statistical analyses were performed with SPSS statistical software （Version 11.0 ; SPSS, 
Tokyo, Japan）.  Differences in age, MMSE results, STAI scores, and results of the olfactory 
detection test between AD patients and healthy subjects were analyzed using the Wilcoxon 
signed-rank test.  Correlation coefcients for the linear regression between the olfactory test 
score and age, MMSE score and olfactory detection level, disease duration and olfactory 
detection level, and therapy duration and olfactory detection level were calculated.  Data in 
the Table 1 are shown as means with standard deviations, and the scattered plots in Figure 
1 indicate the values obtained for each AD patient.
Results
　Detection and recognition scores of healthy subjects and AD patients are shown in Table 
1.  There was no signicant difference in age between healthy subjects and AD patients （P
＞0.05）.  Three out of 16 AD patients were not able to detect the odors, and 14 out of 16 
patients had impaired odor recognition.  There was no difference in detection levels between 
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healthy subjects （n＝11） and AD patients （n＝13） （P＞0.05）.  The MMSE scores were 
signicantly lower in AD patients than in healthy subjects （P＜0.01）.  There was no differ-
ence in state anxiety between the two groups （P＝0.5）.  However, there were signicantly 
lower scores for trait anxiety in AD patients （P＜0.05）.
　Fig. 1 shows the relationships between the measured variables in the 13 AD patients 
exhibiting impaired odor recognition, but intact odor detection ability.  There was no cor-
relation between the olfactory detection score and age （r＝0.2, P＞0.05）, the olfactory 
detection score and the MMSE score （r＝0.2, P＞0.05）, the olfactory detection score and 
disease duration （r＝0.4, P＞0.05）, or the olfactory detection score and therapy duration （r
＝0.1, P＞0.05）.  While there was no correlation between state anxiety score and olfactory 
detection score （r＝0.34, P＞0.05）, there was a signicant negative correlation between the 
trait anxiety score and the olfactory detection score （r＝0.78, P＜0.01）.  Taken together, 
these results indicate that AD patients with a lower olfactory detection score and able to 
detect low concentrations of odor had a higher trait anxiety score.
Discussion
　Most AD patients in this study exhibited the same odor detection sensitivity as healthy 
subjects, with the exception of three patients （Subjects 1, 2 and 3）, but exhibited impaired 
Table 1.　Background data, olfactory test scores, and STAI scores of AD patients
Olfaction Test STAI
Subjects Age Detection Recognition State Trait MMSE
Disease 
Duration （y）
Therapy 
Duration （m）
1 83 impaired impaired 30 25 22 10 60
2 78 impaired impaired 42 37 12 5 36
3 78 impaired impaired 32 29 18 8 36
4 79 2.5 impaired 30 22 22 7 48
5 81 -2 impaired 62 45 26 3 30
6 88 3 impaired 55 35 18 5 36
7 88 -0.8 impaired 40 32 23 2.5 18
8 87 4.5 impaired 24 20 24 2.5 24
9 79 2.6 impaired 54 23 27 7 48
10 82 1.5 impaired 44 29 25 3 2
11 72 0.6 impaired 36 28 26 2.5 31
12 74 0.2 impaired 33 33 23 4 4
13 75 0.6 impaired 38 42 17 4.5 4
14 82 -0.4 impaired 36 38 28 4.5 55
15 71 -1 1.9 28 32 21 3 24
16 77 -0.8 2 49 47 25 2.5 30
AD 79.6±5.2 0.8±1.8 1.9±0.1 39±10 32±8 22±4 4.6±2.2 30±17
Normal 
   Subjects
（77.2±5.1）（0.78±2.1）（0.9±2.1）（39.6±0.7）（＊38.2±0.7）（＊29.6±0.7） ＊p＜0.05
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Fig. 1. Correlation between age, state anxiety scores, trait anxiety scores, MMSE score, disease 
duration, therapy duration, and olfactory detection scores in AD patients.
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odor recognition.  These findings are consistent with a previous study showing that AD 
patients had normal smell detection but severely impaired olfactory identication ability13）. 
The neuropathological mechanisms underlying olfactory impairment remain unknown.  There 
is a debate whether impaired odor detection ability reects impairment at the semantic level 
caused by damage to the Pir cortex, primary olfactory cortex, or cortical-AMG connections. 
Some of the earliest changes in AD patients appear in the olfactory bulb 14） and other 
studies have established that smell pathways are damaged in AD patients, but the maximum 
impact seems to be on the central rather than peripheral nervous system 15）.  Our results 
suggest that odor impairment in AD patients is indicative of damage to the central nervous 
system, namely a dysfunction in cortical-AMG connections.
　In the process of odor detection, odor molecules reach the top of the nasal cavity and 
then interact with olfactory receptor cells that have cilia （dendrites） extending from the cell 
body into the nasal mucosa.  Axons carry impulses to the olfactory bulb when the olfac-
tory receptor is stimulated.  The olfactory bulb then sends signals to the prepiriform and 
Pir cortices, the anterior olfactory nucleus, AMG, olfactory tubercle, and ENT.  The OFC is 
involved in the convergence of higher-order information such as discrimination and repre-
sentation 5, 6）.  Odor recognition is impaired when connections between the AMG, ENT, and 
OFC are damaged in PD8）.  Patients with PD are unable to recognize odors but retain the 
ability to detect odors within the normal range.  Previous studies indicate that the olfactory 
decits in PD have a neuropathological basis different from that of AD.  Our ndings here 
suggest that olfactory dysfunction in AD might result from damage to the central limbic 
areas rather than damage to the peripheral nervous system.
Correlation between detection level and trait anxiety score
　We found that trait anxiety was lower in AD patients than in healthy subjects.  Whereas 
the state anxiety scale evaluates how people feel ‘right now’ in various situations, the trait 
anxiety scale evaluates how people generally feel.  State anxiety scores can change depend-
ing on the situation, but trait scores are generally stable10）.  Subjects with high trait anxiety 
show strong activation in the AMG during exposure to negative emotional stimuli16）, and 
can be sensitive to olfactory stimuli 17）.  Unlike emotional responses, trait anxiety appears 
to be associated with the limbic areas and involve physiological responses co-expressed 
with emotional responses.  Therefore, trait anxiety might be low in AD patients because of 
atrophy to the limbic system, particularly the AMG.  It has been reported that trait anxiety 
level is dependent on amygdala activity 16）, therefore, the low activation of the AMG is 
linked to reduced trait anxiety in AD.
　The trait anxiety scores in AD patients were lower than in healthy subjects, and cor-
related with odor detection sensitivity.  This result suggests that AD patients showing a high 
trait anxiety score tended to have increased odor detection sensitivity.  This correlation was 
not observed in healthy subjects （r＝0.4, P＞0.05）.
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　Among the sensory systems, olfactory perception is a unique process whereby informa-
tion ascends directly to the olfactory limbic areas, bypassing the thalamus, and activates the 
Pir cortex, ENT, and AMG.  Activation of these areas, especially the ENT and AMG, is 
required for odor detection.  We have no direct evidence of a relationship between trait 
anxiety level and the stage of decreased AMG function in AD patients.  It is possible that 
levels of trait anxiety and odor detection can be used to evaluate residual AMG function 
in AD patients.  Further studies using brain imaging technology are thus required to clarify 
the relationship between activation levels in limbic areas and odor detection ability in AD 
patients with low and high trait anxiety.
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